Top Stories: FTC Takes Action Against Drug Benefit Managers Amid Rising Insulin Prices in the U.S.

FTC Sues Drug Benefit Managers

The Federal Trade Commission (FTC) has taken a decisive step in addressing rising insulin costs by suing three major prescription drug benefit managers (PBMs). These lawsuits allege that the companies have conspired to artificially inflate the list prices of insulin.

Impact on Insulin Pricing

• The allegations follow growing concerns regarding the accessibility and affordability of insulin for patients.
• The lawsuit highlights the critical role that PBMs play in determining drug prices and the potential market manipulation.

This action by the FTC is pivotal in revealing potential malpractices in the pricing strategies of these drug middlemen.